Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22218672 | 0.76 | RAB9A (0.71) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL14069303 | 0.75 | ITGB1 (0.55) | MAPTPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14199813 | 0.75 | RAB9A (0.48) | RAB9A | |
| SCHEMBL25106567 | 0.74 | POLB (0.57) | MAPTPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14069333 | 0.74 | RAB9A (0.46) | MAPTPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20236592 | 0.74 | NPC1 (0.69) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL14199838 | 0.74 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL22218895 | 0.72 | FAAH (0.60) | MAPTPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22218547 | 0.71 | ALOX5 (0.58) | MAPTTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22218134 | 0.71 | KMT2A (0.69) | MAPTPOLBRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | MAPT 2145/4885ABL1 11/4885POLB 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.